Online inquiry

IVTScrip™ mRNA-Anti-S, AZD8895(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3451MR)

This product GTTS-WQ3451MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, AZD8895(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3451MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3313MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ASN-100
GTTS-WQ3045MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ13848MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-1193
GTTS-WQ14233MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RG-6107
GTTS-WQ7448MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GBR500
GTTS-WQ3967MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ9851MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA K7153A
GTTS-WQ11380MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI-573
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW